Comparative analysis of vaccine and disease induced immunity and immunological evaluation of COVID-19 vaccines on effectiveness and safety

Bidragets beskrivning

A novel coronavirus, SARS-CoV-2 started the first coronavirus pandemic in early 2020. The virus spreads mainly via respiratory droplets and occasionally the disease leads to a severe lower respiratory tract infection, acute respiratory failure and death. Globally, as of June 2020 there have been nearly 6,5 million cases and 400 000 deaths due to COVID-19 infection. Our research consortium concentrates on analyzing the activation and specificity of antibody and cell-mediated immunity in COVID-19 infected and vaccinated individuals. We intend to identify the viral targets of protective immunity and in longitudinal follow-up studies analyze the natural infection and COVID-19 vaccine-induced immunity at individual and population level. The study has a significant public health impact and the data produced by the project is likely to enhance pandemic preparedness and response as well as to direct coronavirus vaccination policy in Finland.
Visa mer

Startår

2020

Slutår

2022

Beviljade finansiering



Merit Melin Orcid -palvelun logo
500 000 €

Rollen i Finlands Akademis konsortium

Partner

Övriga parter i konsortiet

Partner
Helsingfors universitet (336411)
499 776 €
Leader
Åbo universitet (336410)
700 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt med särskild inriktning

Övriga uppgifter

Finansieringsbeslutets nummer

336431

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Temaområden

Lisätalousarvio III 2020

Identifierade teman

covid, pandemic, vaccines